Back to top
more

Zevra Therapeutics, Inc. (ZVRA)

(Delayed Data from NSDQ)

$4.80 USD

4.80
191,944

-0.09 (-1.84%)

Updated May 14, 2024 04:00 PM ET

After-Market: $4.80 0.00 (0.00%) 6:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ZVRA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Zevra Therapeutics, Inc. [ZVRA]

Reports for Purchase

Showing records 1 - 20 ( 26 total )

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

04/03/2024

Company Report

Pages: 12

4Q EPS Optics Not Material; Looking Forward to Transformational 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

04/01/2024

Daily Note

Pages: 13

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

03/31/2024

Company Report

Pages: 6

4Q23: KP1077 Phase 2 Win, Arimoclomol PDUFA Set, Another AZSTARYS Milestone

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

03/05/2024

Company Report

Pages: 12

Arimoclomol PDUFA Extension Not a Material Delay; Perhaps Even Bolsters View on Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

03/04/2024

Company Report

Pages: 5

Arimoclomol PDUFA Date Pushed to Sept 21, 2024, Not Material In Our View

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

12/28/2023

Company Report

Pages: 12

Updating Our Model For the New Zevra; Target to $15; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

12/27/2023

Company Report

Pages: 5

Arimoclomol NDA Resubmitted On Time, Expecting Late 2Q24 PDUFA Date

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

11/07/2023

Daily Note

Pages: 8

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

11/07/2023

Company Report

Pages: 6

3Q23: Arimoclomol NDA ACER Acquired By YE23, IH Data 1H24, Well Funded; PT to $22

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

10/06/2023

Daily Note

Pages: 10

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

10/06/2023

Company Report

Pages: 6

Data Presented at CNS Annual Meeting Show Long-Term Arimoclomol Benefit

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

10/02/2023

Company Report

Pages: 5

Interim Phase 2 KP1077 Results in IH Show Safety, Final Results in 1H24

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

09/11/2023

Daily Note

Pages: 11

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

09/11/2023

Company Report

Pages: 5

Presents Full Phase 1 CV Safety PK Data for KP1077 Versus Ritalin

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

09/01/2023

Company Report

Pages: 6

To Acquire ACER By YE23, Making Good on Orphan Drug Company Promise; $25 PT

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

08/14/2023

Daily Note

Pages: 7

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

08/14/2023

Company Report

Pages: 6

2Q23: IH Data Arimoclomol NDA in 2H23, Ample Funds Provide Flexibility

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Zevra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

05/16/2023

Daily Note

Pages: 13

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party